EcoDrugPlus

Arginine Vasopressin Receptor 2

Ensembl ID : ENSNBRG00000011537
Gene Symbol: AVPR2
3 Cross references
147 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSNBRG00000015029
Gene Symbol: AVPR2
3 Cross references
178 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSNBRG00000024000
Gene Symbol: AVPR2
1 Cross references
147 Possible Orthologues:

Aromatase-Like

Ensembl ID : ENSNBRG00000023814
Gene Symbol: LOC102783408
3 Cross references
249 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 1-Like

Ensembl ID : ENSNBRG00000021254
Gene Symbol: LOC102780034
3 Cross references
190 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 1-Like

Ensembl ID : ENSNBRG00000008407
Gene Symbol: LOC102776639
2 Cross references
191 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 2-Like

Ensembl ID : ENSNBRG00000022612
Gene Symbol: LOC102791474
2 Cross references
185 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 3-Like

Ensembl ID : ENSNBRG00000008484
Gene Symbol: LOC102782957
3 Cross references
211 Possible Orthologues:

Aurora Kinase A-B-Like

Ensembl ID : ENSNBRG00000004811
Gene Symbol: LOC102787914
3 Cross references
232 Possible Orthologues:

Aurora Kinase B-Like

Ensembl ID : ENSNBRG00000024390
Gene Symbol: LOC102779049
3 Cross references
205 Possible Orthologues:

Bcl-2-Like Protein 1-Like

Ensembl ID : ENSNBRG00000020345
Gene Symbol: LOC102780642
4 Cross references
226 Possible Orthologues:

Bcl-2-Like Protein 1-Like

Ensembl ID : ENSNBRG00000023195
Gene Symbol: LOC102798100
2 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).